CheckMate-017

一行要約

プラチナ既治療の扁平上皮 NSCLC 2L における Nivolumab vs Docetaxel の phase III。OS HR 0.59 (9.2 vs 6.0 mo) で有意差を示し、扁平上皮 NSCLC における初の免疫チェックポイント阻害薬承認を導いた landmark 試験。PD-L1 発現によらず OS benefit が認められた点が CheckMate-057 との重要な違い。

試験デザイン

• 対象: Stage IIIB/IV 扁平上皮 NSCLC、プラチナ製剤を含む 1 レジメン後に進行、ECOG PS 0-1、N=272 (1:1)
• 介入群 (n=135) : Nivolumab 3 mg/kg Q2W
• 対照群 (n=137) : Docetaxel 75 mg/m2 Q3W
• 層別化: 地域 (US vs EU vs RoW), 先行治療ライン数 (1 vs 2)
• 主要評価項目: OS
• 副次評価項目: ORR、PFS、PD-L1 発現別の有効性

主要結果

• OS (primary) : HR 0.59 (95% CI 0.44–0.79, p<0.001)、median 9.2 vs 6.0 mo
• 1-year OS rate: 42% vs 24%
• PFS: HR 0.62 (95% CI 0.47–0.81, p<0.001)、median 3.5 vs 2.8 mo
• ORR: 20% vs 9% (p=0.008)
• PD-L1 発現別: PD-L1 発現レベルに関係なく OS benefit が認められた (PD-L1 <1% でも HR 0.63)。予測バイオマーカーとしての PD-L1 は有意でなく、扁平上皮組織型自体が IO 感受性に寄与
• Grade 3-4 AE: Nivolumab 7% vs Docetaxel 55% (治療関連)。Nivolumab は免疫関連 AE (肺臓炎、甲状腺障害) が主だが重篤例は稀

臨床的意義

• 扁平上皮 NSCLC 初の IO 承認: 2015 年に FDA 承認を取得し、2L 扁平上皮 NSCLC の標準治療を Docetaxel から Nivolumab に転換
• PD-L1 非依存性: 非扁平上皮を対象とした CheckMate-057 では PD-L1 高発現群でのみ OS benefit が顕著であったのに対し、本試験では PD-L1 発現によらず benefit が認められ、扁平上皮では PD-L1 testing なしでの IO 使用が許容される根拠となった
• IO 2L 標準化の第一歩: KEYNOTE-010、CheckMate-057 と合わせて NSCLC 2L の治療パラダイムを化学療法から IO に転換。その後の 1L IO 開発 (KEYNOTE-024、CheckMate-227) への基盤となった
• 安全性プロファイル: Grade 3-4 AE 発生率の著明な低下は QOL 改善を示唆し、高齢者や PS 不良例への IO 適用拡大の根拠にもなった

Open Questions

• 2L IO の位置づけ変化: 1L IO+化療 (KEYNOTE-189、KEYNOTE-407) 普及後、IO-naive 2L は減少。IO rechallenge / IO 2L の役割は再定義が必要
• TMB / 遺伝子変異負荷の追加的予測能: PD-L1 非依存の benefit を TMB で層別化できるか
• 扁平上皮 NSCLC の分子サブタイプと IO 応答: FGFR / PI3K / SOX2 amplification 等と IO 効果の関連

重要論文 Top 10

1. Brahmer et al. NEnglJMed 2015 — Primary publication — OS HR 0.59、扁平上皮 NSCLC 初の IO 承認根拠
2. Borghaei et al. NEnglJMed 2015 (CheckMate-057) — 非扁平上皮での companion trial、PD-L1 依存性の対比
3. Borghaei et al. JClinOncol 2021 — 5-year OS 12% — durable benefit の確認
4. Herbst et al. Lancet 2016 (KEYNOTE-010) — Pembrolizumab 2L — PD-L1 cutoff 戦略の確立
5. Rittmeyer et al. Lancet 2017 (OAK) — Atezolizumab 2L — PD-L1 IC 別解析

関連エンティティ・概念

• 薬剤: Nivolumab / Docetaxel
• 関連試験: CheckMate-057 (非扁平上皮 2L) / KEYNOTE-010 (Pembrolizumab 2L) / CheckMate-227 (1L IO+IO) / KEYNOTE-407 (1L 扁平上皮 IO+化療)
• 関連遺伝子: PD-L1
• 関連概念: irAE
• ドメイン: lung-cancer-treatment

関連論文

直近 30 件のみ表示中 (関連 65 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Immunotherapy

• Schoenfeld et al. CancerCell 2020 — Acquired resistance to immune checkpoint inhibitors
• Hakozaki et al. CancerImmunolRes 2020 — The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung

Basic-Liquid-biopsy

• Zhang et al. CancerDiscov 2020 — Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune

Basic-Neutrophil and myeloid cell

• Schalper et al. NatMed 2020 — Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of

Basic-Tumor microenvironment

• Bullock et al. LifeSciAlliance 2019 — Tumor-intrinsic response to IFNgamma shapes the tumor microenvironment and anti-PD-1 response in NSCLC

Clinical-NSCLC-Driver negative

• Planchard et al. AnnOncol 2018 — Metastatic non-small cell lung cancer ESMO clinical practice guidelines for diagnosis, treatment and follow-up
• Doroshow et al. ClinCancerRes 2019 — Immunotherapy in non-small cell lung cancer facts and hopes
• Carbone et al. ESMOOpen 2025 — Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung
• Felip et al. EurJCancer 2020 — CheckMate 171 A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung
• Li et al. FrontImmunol 2026 — The application and challenges of immune checkpoint inhibitors in lung cancer therapy
• Gettinger et al. JAMAOncol 2021 — Nivolumab plus ipilimumab vs nivolumab for previously treated patients with stage IV squamous cell lung cancer the
• Passaro et al. JClinOncol 2019 — Immunotherapy in non-small-cell lung cancer patients with performance status 2 clinical decision making with scant
• Waterhouse et al. JClinOncol 2020 — Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer CheckMate
• Borghaei et al. JClinOncol 2021 — Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057 nivolumab versus docetaxel in previously
• Kato et al. JImmunotherCancer 2020 — Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with
• Spigel et al. JThoracOncol 2019 — Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients
• Mazieres et al. JThoracOncol 2021 — Atezolizumab versus docetaxel in pretreated patients with NSCLC final results from the randomized phase 2 POPLAR and
• Crino et al. LungCancer 2019 — Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
• Kaira et al. Medicina(Kaunas) 2021 — Clinical effectiveness of immune checkpoint inhibitors in non-small-cell lung cancer with a poor performance status
• Forde et al. NEnglJMed 2022 — Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer
• Barlesi et al. OncoImmunology 2020 — Effectiveness and safety of nivolumab in the treatment of lung cancer patients in france preliminary results from the
• Barlesi et al. OncoImmunology 2025 — Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer
• Cengiz et al. SciRep 2026 — Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients

Clinical-NSCLC-EGFR

• Yoshida et al. AnnOncol 2018 — Nivolumab in non-small-cell lung cancer with EGFR mutation

Clinical-SCLC

• Tian et al. JHematolOncol 2019 — Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small
• Ready et al. JThoracOncol 2019 — Third-line nivolumab monotherapy in recurrent SCLC CheckMate 032

Clinical-Thymic

• Kaira et al. Cancers 2021 — Perspective of immune checkpoint inhibitors in thymic carcinoma

Clinical-irAE

• Sata et al. CancerSci 2021 — Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer
• Shankar et al. JAMAOncol 2020 — Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell
• Asao et al. LungCancer 2024 — Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune